Tscan therapeutics to participate in the h.c. wainwright 3rd annual cell therapy virtual conference

Waltham, mass., feb. 18, 2025 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx), a clinical-stage biotechnology company focused on the development of t cell receptor (tcr)-engineered t cell (tcr-t) therapies for the treatment of patients with cancer, today announced that the company will participate in a fireside chat at the h.c. wainwright 3rd annual cell therapy virtual conference on tuesday, february 25, 2025 at 10:00 a.m. eastern time.
TCRX Ratings Summary
TCRX Quant Ranking